Sevista (Ormeloxifene)
Sevista is ormeloxifene, a selective estrogen receptor modulator (SERM) used primarily for the treatment of dysfunctional uterine bleeding (DUB) in women. 1
Mechanism and Clinical Use
Ormeloxifene acts as a tissue-selective estrogen receptor modulator, with anti-estrogenic effects on the endometrium that reduce menstrual blood loss in women with DUB. 1
The standard dosing regimen is 60 mg twice weekly for 3 months, followed by 60 mg once weekly for an additional 3 months. 1
Clinical Efficacy in Dysfunctional Uterine Bleeding
Treatment with ormeloxifene produces statistically significant improvements in hemoglobin levels (p < 0.001) and statistically significant reductions in endometrial thickness (p < 0.001) after 3 months of therapy. 1
Ormeloxifene can be used as an effective medical therapy for DUB, particularly in women who wish to avoid hormonal contraceptives or more invasive interventions. 1
Important Distinction from Other SERMs
Sevista (ormeloxifene) should not be confused with Evista (raloxifene), which is a different SERM used for osteoporosis prevention and breast cancer risk reduction in postmenopausal women. 2
Ormeloxifene has no established role in osteoporosis or breast cancer prevention, unlike raloxifene, which reduces invasive breast cancer incidence by 66% over 8 years in postmenopausal women with osteoporosis. 2
Clinical Context
For women presenting with excessive menstrual bleeding without identified organic pathology, ormeloxifene offers a non-hormonal contraceptive alternative that can be taken intermittently rather than daily, with demonstrated efficacy in reducing blood loss and improving anemia. 1